1-(1-adamantyl)cyclohexanamine | 1621387-64-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(1-adamantyl)cyclohexanamine
• 英文别名: 1-(1-Adamantyl)cyclohexan-1-amine；1-(1-adamantyl)cyclohexan-1-amine
• CAS: 1621387-64-1
• 化学式: C₁₆H₂₇N
• 分子量: 233.397
• InChiKey: QQHMVIJSUMCVSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-溴金刚烷 在 lithium aluminium tetrahydride 、 sodium azide 、 lithium 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 33.0h， 生成 1-(1-adamantyl)cyclohexanamine
  参考文献：
  名称：

  Binding and Proton Blockage by Amantadine Variants of the Influenza M2_WT and M2_S31N Explained

  摘要：

  While aminoadamantanes are well-established inhibitors of the influenza A M2 proton channel, the mechanisms by which they are rendered ineffective against M2(s31N) are unclear. Solid state NMR, isothermal titration calorimetry, electrophysiology, antiviral assays, and molecular dynamics simulations suggest stronger binding interactions for aminoadamantanes to M2(WT). compared to negligible or weak binding to M2s31N. This is due to reshaping of the M2 pore when N31 is present, which, in contrast to wild-type (WT), leads (A) to the loss of the V27 pocket for the adamantyl cage and to a predominant orientation of the ligand's ammonium group toward the N-terminus and (B) to the lack of a helical kink upon ligand binding. The kink, which reduces the tilt of the C-terminal helical domain relative to the bilayer normal, includes the W41 primary gate for proton conductance and may prevent the gate from opening, representing an alternative view for how these drugs prevent proton conductance.

  DOI：

  10.1021/acs.jmedchem.6b01115

文献信息

• Approaches to primary tert-alkyl amines as building blocks
  作者：Christina Tzitzoglaki、Antonios Drakopoulos、Athina Konstantinidi、Ioannis Stylianakis、Marianna Stampolaki、Antonios Kolocouris

  DOI：10.1016/j.tet.2019.06.016

  日期：2019.8

  Primary tert-alkyl amines include analogues of amantadine, a fragment commonly linked to pharmacophoric groups to enhance biological activity. The preparation of primary tert-alkyl amines is considered to be a difficult problem. Four synthetic procedures, some of which have been previously reported for the synthesis of amines with primary (RCH2NH2) or secondary (RR'CHNH2) alkyl and/or aryl groups,

  初级叔烷基胺包括金刚烷胺的类似物，通常连接到药效基团的片段，以提高生物活性。伯叔烷基胺的制备被认为是一个难题。四个合成步骤，其中一些已经用于与胺的合成已有报道初级（RCH 2 NH 2）或仲（RR'CHNH 2）烷基和/或芳基，伯合成进行了测试叔烷基胺（RR'R''CNH 2）包括金刚烷加合物在内的脂族系列。这些程序包括在形成和还原的叔烷基叠氮化物，在标准和改良条件Ritter反应，在加入有机金属试剂以ñ -叔丁基亚磺酰基酮亚胺和一锅在路易斯酸的存在下，Τi（IPRO）腈和有机金属试剂之间的反应4或CeCl 3.对于伯叔烷基胺，尚未开发这些合成途径。当前缺乏对伯叔烷基胺的合成路线的研究。研究了每种方法的反应条件和底物限制，第一种方法是最通用的方法，也适用于带有大分子加合物的化合物。
• Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
  申请人：——

  公开号：US20040087658A1

  公开（公告）日：2004-05-06

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  该发明涉及一种新型药物组合疗法，可用于治疗痴呆，包括给予一种1-氨基环己烷衍生物，如美万特或奈拉美喜，以及一种乙酰胆碱酯酶抑制剂（AChEI），如加兰他明、他克林、多奈哌齐或利伐替明。
• NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
  申请人：——

  公开号：US20040019118A1

  公开（公告）日：2004-01-29

  Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemic-ally-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.

  氨基环己烷和氨基烷基环己烷化合物作为NMDA受体拮抗剂在系统上具有活性，对抑制微管相关蛋白tau异常过度磷酸化有效。涉及治疗由于或与微管相关蛋白tau异常过度磷酸化相关的疾病的方法，以及包含这些化合物的药物组合物。
• [EN] METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR AMÉLIORER LA FONCTION COGNITIVE
  申请人：GALLAGHER MICHELA

  公开号：WO2014153180A1

  公开（公告）日：2014-09-25

  This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a a5 -containing GABAA receptor agonist in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

  本发明涉及用于治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法和组合物。具体而言，它涉及在需要或有风险的受试者中使用含有a5的GABAA受体激动剂与美拉替特或其衍生物或类似物结合，用于治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于患有或有风险患上与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症或躁郁症、肌萎缩侧索硬化、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症、强迫行为和物质成瘾。
• METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE
  申请人：Hung David T.

  公开号：US20100152108A1

  公开（公告）日：2010-06-17

  The invention provides methods and combination therapies for treating and/or preventing and/or slowing the onset and/or development of Alzheimer's disease using a hydrogenated pyrido (4,3-b) indole (e.g., dimebon) in conjunction with another compound, pharmaceutically acceptable salt thereof or therapy for Alzheimer's disease.

  该发明提供了一种治疗和/或预防和/或减缓阿尔茨海默病的发作和/或发展的方法和联合疗法，使用氢化吡啶并哌啶(例如二甲苯胺)与另一化合物、其药用盐或治疗阿尔茨海默病的疗法结合。